Yissum - Research Development Company of the Hebrew University

Research & Services | Discovering the Connection Between the Immune Response and Cancer

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Research Services and Capabilities · Israel

Summary of the technology

Research & Services | Discovering the Connection Between the Immune Response and Cancer
Project ID : 34-2010-2390

Description of the technology

New approaches to developing reagents that block cancers' support mechanism


Life Sciences and Biotechnology, Medicine

Professor Ben Neriah's Laboratory for Immunology and Cancer Research, The Lautenberg Center for General and Tumor Immunology, Faculty of Medicine

Research Capabilities

  • Studying signal transduction pathways incorporating phosphorylation and ubiquitination, in particular the NF-κB and Wnt signaling pathways
  • Understanding the regulation of phosphorylation and the destruction machineries of β-catenin, IκB, key regulators of the Wnt and the NF-κB pathways
  • Identifying Wnt signaling molecules and their mechanisms of action
  • Studying the biological consequences of mutations in these pathways in specific animal models with relevance to human disease, particularly cancer, inflammation and immunity


The laboratory, working in close collaboration with Dr. Eli Pikarsky's group, develops proprietary specific animal models for studying the interrelation between the immune system and cancer development.

Research Background

Research carried out in Professor Ben-Neriah's lab is focused on unravelling the connections between the immune response mechanism and cancer development in order to develop neutralizing reagents that intervene with the immune system and block its support for cancer development.

Researcher and Research Interests

Professor Yinon Ben-Neriah, Chairperson, Immunology and Cancer Research, Faculty of Medicine, also serves as Visiting Professor, Department of Systems Biology, Harvard Medical School. Author of numerous peer-reviewed papers and elected Member of the European Molecular Biology Organization and the European Cancer Forum. Professor Ben-Neriah earned degrees at Tel Aviv University Medical School (M.D.), Weizmann Institute of Science, Rehovot, Israel (Ph.D.) and Whitehead Institute at the Massachusetts Institute of Technology, Cambridge (Post-doc). For his ongoing cancer research, he has been honored with the Teva Founders Prize, George and Eva Klein Prize in Cancer Research, Israel Science Foundation, Landau Prize, and many others.

Dr. Eli Pikarsky, a clinical and experimental pathologist who’s main research focus in the lab is neoplastic diseases. Most of the projects that are currently pursued in the lab involve animal models of cancer, using genetically engineered mice and other models of spontaneous carcinogenesis.

Available Resources

Unique animal models of gastrointestinal cancer and mouse models simulating inhibitory drug actions

Laboratory Contact

Professor Yinon Ben Neriah, yinon@cc.huji.ac.il, +972-2-675-8718

Dr. Eli Pikarsky,peli@hadassah.org.il, +972-2-675-8202

Elad Horwitz, Graduate student,eladh@ekmd.huji.ac.il

Project manager

Itzik Goldwaser
VP, Head of Research Collaborations

Project researchers

Yinon Ben-Neriah
HUJI, School of Medicine - IMRIC
Immunology and Cancer Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Clean Industrial Technologies
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Clinical Medicine
  • Anatomy, Pathology, Immunology, Physiology
  • Agro and Marine biotech
  • Other Medical/Health Related
  • Therapeutic
  • Diagnostic
  • Other (uncategorised)
  • Research Collaboration
  • Life Science & Biotechnology

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.